Literature DB >> 31656656

Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer.

Yuki Takahashi1,2, Hirofumi Adachi1, Yasushi Mizukami1, Hiroshi Yokouchi3, Satoshi Oizumi3, Atsushi Watanabe2.   

Abstract

BACKGROUND: The efficacy of curative-intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with certain types of oligometastases, particularly brain and adrenal metastases, has previously been described. We investigated the outcomes of curative-intent pulmonary resection for NSCLC patients with synchronous isolated bone metastases, which have been less clear to date.
METHODS: We retrospectively reviewed the clinical and pathological records of 41 patients with NSCLC and synchronous isolated bone metastases who underwent radical treatments (surgery and/or chemotherapy and/or radiotherapy) for both their primary tumors and bone metastases at the National Hospital Organization, Hokkaido Cancer Center, between 2008 and 2013.
RESULTS: Nine of the 41 patients underwent pulmonary primary tumor resection; the rate of clinical N0-1 disease among these 9 patients (100%) was significantly higher than that among the 32 patients who did not undergo resection (34.4%). The five-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates of the nine patients who underwent pulmonary resection were 66.7%, 55.6%, and 44.4%, respectively. On multivariate analysis, the predictors of longer OS among all 41 patients were primary site resection [hazard ratio (HR) =4.18, 95% CI, 1.20-14.6, P=0.025] and epidermal growth factor receptor (EGFR) mutation (HR =3.30, 95% CI, 1.08-10.1, P=0.036). The former was also a predictor of longer PFS (HR =3.75, 95% CI, 1.27-11.0, P=0.016).
CONCLUSIONS: Patients with clinical N0-1 NSCLC and synchronous isolated bone metastases may achieve longer survival rates following primary lung tumor resection. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Surgery; bone metastasis; non-small cell lung cancer (NSCLC)

Year:  2019        PMID: 31656656      PMCID: PMC6790437          DOI: 10.21037/jtd.2019.09.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

1.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Giuseppe Giaccone; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-01       Impact factor: 3.840

2.  Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis.

Authors:  Q Xu; Y Wang; H Liu; S Meng; S Zhou; J Xu; G Schmid-Bindert; C Zhou
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

Review 3.  Current Landscape of Targeted Therapy in Lung Cancer.

Authors:  Manasi K Mayekar; Trever G Bivona
Journal:  Clin Pharmacol Ther       Date:  2017-09-25       Impact factor: 6.875

4.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

Review 5.  Surgical approach in oligometastatic non-small cell lung cancer.

Authors:  Davide Patrini; Nikolaos Panagiotopoulos; Benedetta Bedetti; Sofoklis Mitsos; Roberto Crisci; Piergiorgio Solli; Luca Bertolaccini; Marco Scarci
Journal:  Ann Transl Med       Date:  2018-03

6.  Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience.

Authors:  Maria Teresa Congedo; Alfredo Cesario; Filippo Lococo; Chiara De Waure; Giovanni Apolone; Elisa Meacci; Sergio Cavuto; Pierluigi Granone
Journal:  J Thorac Cardiovasc Surg       Date:  2012-06-17       Impact factor: 5.209

7.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

8.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

9.  Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer.

Authors:  Li Zhang; Zhixin Gong
Journal:  Med Sci Monit       Date:  2017-08-24

10.  Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.

Authors:  Xin Li; Han Qi; Gou Qing; Ze Song; Lin Xie; Fei Cao; Xiaoming Chen; Weijun Fan
Journal:  Thorac Cancer       Date:  2018-06-20       Impact factor: 3.500

View more
  3 in total

1.  The Prognostic Impact of Lymph Node Dissection on Primary Tumor Resection for Stage IV Non-Small Cell Lung Cancer: A Population-Based Study.

Authors:  Yudong Zhang; Yichi Zhang; Xinxin Cheng; Keyao Dai; Bo Xu; Shujun Liang; Minsheng Chen; Honglang Zhang; Zhenguang Chen
Journal:  Front Oncol       Date:  2022-05-05       Impact factor: 5.738

2.  Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.

Authors:  Kan Deng; Shuping Li; Jian Zhang; Xiande Ye; Kai Yao; Ying Li; Jianru Xiao
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 3.005

3.  Surgical Survival Benefits With Different Metastatic Patterns for Stage IV Extrathoracic Metastatic Non-Small Cell Lung Cancer: A SEER-Based Study.

Authors:  Ce Chao; Yongxiang Qian; Xihao Li; Chen Sang; Bin Wang; Xiao-Ying Zhang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.